Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Opendoor Technologies Inc (OPEN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Opendoor Technologies Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.91 (market cap $4.49B), while Opendoor Technologies Inc trades at $4.73 (market cap $4.62B). The key difference: ACADIA Pharmaceuticals Inc. and Opendoor Technologies Inc are close in size by market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Opendoor Technologies Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | OPEN | |
|---|---|---|
Market Cap | $4.49B | $4.62B |
Sector | Health | Real Estate |
52-Week High | $28.06 | $10.52 |
52-Week Low | $20.06 | $0.73 |
Enterprise Value | $3.69B | $4.96B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Opendoor Technologies (OPEN) trades at $4.79, down 2.24% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported a net loss of $1.30 billion on $4.37 billion revenue in 2025, with a negative net income margin of -35.25%. Recent news highlights a new CEO, a shift to the Opendoor 2.0 model, and the closure of India operations to focus on AI-driven efficiencies.
The outlook remains challenging with persistent losses and a highly leveraged balance sheet, though cost discipline and AI integration offer potential for margin improvement. Key risks include housing market volatility and high debt levels. Analyst consensus is cautious with 65.39% hold ratings, reflecting uncertainty around the path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Opendoor Technologies Inc
Opendoor Technologies Inc is a digital platform for residential real estate. This platform enables customers to buy and sell houses online. It generates revenue through home sales, along with other revenue from real estate services.
Read more on OPEN →
